Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Total Current Liabilities (2016 - 2026)

Summit Therapeutics filings provide 13 years of Total Current Liabilities readings, the most recent being $83.3 million for Q1 2026.

  • Quarterly Total Current Liabilities rose 138.74% to $83.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $83.3 million through Mar 2026, up 138.74% year-over-year, with the annual reading at $73.0 million for FY2025, 74.91% up from the prior year.
  • Total Current Liabilities hit $83.3 million in Q1 2026 for Summit Therapeutics, up from $73.0 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $140.2 million in Q2 2024 and bottomed at $11.9 million in Q2 2023.
  • Average Total Current Liabilities over 5 years is $49.3 million, with a median of $38.8 million recorded in 2022.
  • The largest annual shift saw Total Current Liabilities tumbled 68.89% in 2022 before it surged 1074.82% in 2024.
  • Summit Therapeutics' Total Current Liabilities stood at $38.8 million in 2022, then tumbled by 47.39% to $20.4 million in 2023, then soared by 104.5% to $41.7 million in 2024, then skyrocketed by 74.91% to $73.0 million in 2025, then rose by 14.08% to $83.3 million in 2026.
  • Per Business Quant, the three most recent readings for SMMT's Total Current Liabilities are $83.3 million (Q1 2026), $73.0 million (Q4 2025), and $64.9 million (Q3 2025).